This Month in Review article featured a variety of notable updates in the field of pulmonology covered in September 2024.

In part 5 of 5, experts discuss ongoing unmet needs and future research priorities in schizophrenia management.

In part 4 of 5, experts discuss medication adherence to schizophrenia treatments, particularly of xanomeline and trospium choloride capsules for schizophrenia.

In part 3 of 5, experts discuss the pivotal trials evaulating xanomeline and trospium chloride capsules (Cobenfy) for schizophrenia.

In part 2 of 5, experts discuss the unique mechanism of xanomeline and trospium choloride capsules for the treatment of schizozphrenia.

In part 1 of 5, panel moderator gives an overview of the Special Report focusing on the approval of Xanomeline and tropism chloride capsules for schizophrenia.

Time-restricted eating, even without calorie restriction, improved glycemic control and cardiometabolic health in patients with metabolic syndrome.

Education and employment, social and emotional functioning, and healthcare access are notable factors influencing pain in sickle cell disease.

In the allergy news space, this Month in Review highlights some of the most significant stories covered by the editorial team.

An interim analysis of the PRO-SPIRIT study compared outcomes at 3 months after starting new treatments for psoriatic arthritis.

In addition to the Breakthrough Therapy Designation, Boehringer Ingelheim announced the initiation of 2 phase 3 trials in adults with MASH and fibrosis and compensated MASH cirrhosis.

Findings highlight HCV infection burden among people without injection drug use, a known risk factor for HCV, and call for universal testing to better capture these individuals.

The biosimilars month in review highlights a new approval and 2023 cost savings

This retrospective analysis examined the current management of early and late anemia in a representative sample of the kidney transplant population in Spain.

These new data provide additional evidence for a range of benzene concentrations detected by in over-the-counter drug products with BPO maintained at room temperature.

A recent study shows the FDA's black-box warnings on antidepressants have led to decreased usage among youth, with an increase in suicide attempts and deaths observed.

This September 2024 month in review spotlights our top coverage of recent nephrology pipeline updates, guidelines, and research.

APAC President Laura Ross, PA-C, shares insights from the RhAPP conference, discussing autoimmune disease, cardiovascular risks, and the importance of interdisciplinary care.

Mease discussed the importance of comparator studies in a growing treatment landscape for PsA.

Anemia is frequently observed in primary care patients with HF and is linked to worse prognosis and comorbidities, including cancer.

The decision by the FDA follows an announcement by Biofrontera that there were no safety issues found following the submission of the medication’s supplemental New Drug Application.

Looking to the future of atopic dermatitis treatment, the panel discusses ongoing research and promising emerging therapies.

Medical experts discuss disease control with abrocitinib or upadacitinib in patients previously taking dupilumab and explain the circumstances under which they would switch a patient to a JAK inhibitor.

Medical experts discuss the importance of setting treatment expectations and maintaining dialogue with patients about targets and explain how to decide on a new treatment when switching.

In this Month in Review, we highlighted some of the most notable stories covered in the dermatology space during September 2024.